Agency warns: European drugs lose effectiveness against coronavirus variants

The European Medicines Agency has warned that drugs approved in the European Union based on monoclonal antibodies may not be effective against new mutations of the Corona virus.

The European Agency issued this warning today, Friday, noting that “these monoclonal antibodies are designed to neutralize the virus by binding to the spike protein on its surface.”

In her warning, she added: “However, the new strains have mutations in this protein that could reduce the ability of antibodies to bind to it.”

Recent laboratory studies show that monoclonal antibodies targeting the spike protein spike proteins are ineffective at neutralizing Omicron strain variants and other mutations that are expected to become dominant in the European Union in the coming weeks.

Source: TASS